If you have been reading about Albumin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Kratom contains at least 54 alkaloids. These include mitragynine, 7-hydroxymitragynine (7-HMG), speciociliatine, paynantheine, corynantheidine, speciogynine, mitraphylline, rhynchophylline, mitralactonal, raubasine, and mitragynaline. The alkaloids mitragynine and 7-hydroxymitragynine are responsible for many of the complex effects of kratom, but other alkaloids may also contribute synergistically. The effects of both mitragynine and 7-HMG remain disputed despite substantial study. Both are partial agonists of the μ-opioid receptor. While most data indicates agonism at all three opioid receptors, other data suggests the alkaloids are antagonists of the δ-opioid receptor with low affinity for the κ-opioid receptor. 7-HMG appears to have higher affinity at the μ-opioid receptor than mitragynine. These compounds display functional selectivity and do not activate the β-arrestin pathway which may be partly responsible for the respiratory depression, constipation, and sedation associated with traditional opioids. Both mitragynine and 7-HMG readily cross the blood–brain barrier. Mitragynine also appears to inhibit COX-2, block L-type and T-type calcium channels, and interact with other receptors in the brain including 5-HT2C and 5-HT7 serotonin receptors, D2 dopamine receptors, and A2A adenosine receptors. Mitragynine stimulates α2-adrenergic receptors, inhibiting the release of norepinephrine (noradrenaline); other compounds in this class include dexmedetomidine, which is used for sedation, and clonidine, which is used to manage anxiety and some symptoms of opioid withdrawal.
America's immigrant population is by far the world's largest in absolute terms. In 2022, there were 87.7 million immigrants and U.S.-born children of immigrants in the United States, accounting for nearly 27% of the overall U.S. population. In 2017, out of the U.S. foreign-born population, some 45% (20.7 million) were naturalized citizens, 27% (12.3 million) were lawful permanent residents, 6% (2.2 million) were temporary lawful residents, and 23% (10.5 million) were unauthorized immigrants. In 2019, the top countries of origin for immigrants were Mexico (24% of immigrants), India (6%), China (5%), the Philippines (4.5%), and El Salvador (3%). In fiscal year 2022, over one million immigrants (most of whom entered through family reunification) were granted legal residence. The undocumented immigrant population in the U.S. reached a record high of 14 million in 2023.
== Early life and education == Caldwell Dyson was born in Arcadia, California. She is the younger of two girls. In the early 1980s, she and her family moved to Beaumont, California, where her father worked as an electrician and where she attended junior high school and high school. Her recreational interests include running, weight training, hiking, softball, basketball, and auto repair and maintenance. She attended California State University, Fullerton, where she competed on the CSUF Titans' track and field team as a sprinter and long jumper. As an undergraduate researcher at California State University, Fullerton, she designed, constructed and implemented electronics and hardware associated with a laser-ionization, time-of-flight mass spectrometer for studying atmospherically relevant gas-phase chemistry. She also worked as a lab assistant in the university's research and instructional safety office, where she performed environmental monitoring of laboratories using hazardous chemicals and radioactive materials and calibrated survey instruments and helped process chemical and radioactive waste. During college and after it, she also worked as an electrician and inside wireman for her father's electrical contracting company, where she performed commercial and light industrial construction. At the University of California, Davis, Caldwell Dyson taught general chemistry laboratory and began her graduate research.
=== COVID-19 pandemic === In April 2020, Gavi's CEO Seth Berkley commented that the COVID-19 pandemic needed a global response whereby the best global facilities for separate parts of the processes should then be integrated into a global process. He said he hoped that the G20 countries should work together with a budget of tens of billions of dollars, and that individual countries should be prepared for finished vaccines to be allocated according to greatest need. In September 2020, Gavi was announced as one of the organisations leading the COVAX vaccine allocation plan, created to ensure that any new COVID-19 vaccine would be shared equally between the world's richest and poorest countries. The following month, Gavi announced the approval of up to $150 million to help 92 low- and middle-income countries prepare for the delivery of future COVID-19 vaccines, including technical assistance and cold chain equipment. In January 2021, Seth Berkley announced that Gavi hoped to deliver 145 to 150 million doses of COVID-19 vaccines in the first quarter of 2021 and 500 million doses in the second quarter, and then 1.5 billion in the second half of the year. In January 2022, The Washington Post reported that following 309 million coronavirus vaccine doses being delivered in December 2021, COVAX had delivered over 1 billion for the pandemic.
Sources: en.wikipedia.org
C.; Schwab, M.; Viegas, M. H.; Roseboom, T. J. (2015). "Prenatal Undernutrition and Leukocyte Telomere Length in Late Adulthood". The American Journal of Clinical Nutrition. 102 (3): 655–660. doi:10.3945/ajcn.115.112326. PMID 26178721. S2CID 4493294. Chen, R.; et al. (2012). "Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes". Cell. 148 (6): 1293–1507. doi:10.1016/j.cell.2012.02.009. PMC 3341616. PMID 22424236. Bernardes De Jesus, B.; Schneeberger, K.; Vera, E.; Tejera, A.; Harley, C. B.; Blasco, M. A. (2011). "The Telomerase Activator TA-65". Aging Cell. 10 (4): 604–621. doi:10.1111/j.1474-9726.2011.00700.x. PMC 3627294. PMID 21426483.
=== Advantages === Advantages include low fragmentation: only a small amount of energy is transferred during the ionization process (compared to e.g. electron ionization), therefore fragmentation is suppressed and the obtained mass spectra are easily interpretable. No sample preparation is necessary: VOC-containing air and headspaces over liquids can be analyzed directly, in real time. A typical response time of 100 ms enables online monitoring. Absolute concentrations are obtained directly without previous calibration measurements. Due to the simple design and the low number of parts needed for a PTR-MS instrument, it can be built in into space saving and even mobile housings. PTR-MS operation requires only electric power and a small amount of distilled water. Unlike other techniques, no gas cylinders are needed for buffer gas or calibration standards.
Ambala district: Centre of Excellence for Litchi, announced in FY2025-26. Yamunanagar district: Centre of Excellence for strawberry, announced in FY2025-26. Karnal district: Centre of Excellence for Vegetables, Gharaunda, established 7.01.2011. Karnal district: Potato Technology Centre, Shamgarh, established 06.04.2016. Kurukshetra district: Centre for Subtropical Fruits, Ladwa, established 06.04.2016. Kurukshetra district: Horticulture Integrated Bee Keeping, Ram Nagar, post office Chaduni Jattan, established 10.11.2017. Rohtak district: Hi-tech Greenhouse Seedling Centre, established 17.12.2013. Jhajjar district: Center of Excellence for Flowers, Munimpur, established 2022. Gurugram district: Hi-tech Greenhouse Seedling Centre, established 17.12.2013. Nuh district: Center of Excellence for Onions, Pinangwan, established 2022. Palwal district: Integrated Horticulture Development, Centre, Hodal, established 13.10.2018. Mahendergarh district: Integrated Horticulture Development Centre, Sundrah village on Ateli-Kanina road, established 01.09.2019. Bhiwani district: Centre of excellence for semi-arid horticulture, Gignaw, established 2022. Hisar district: Multi Crops Demonstration Centre, Barwala, established 2022. Hisar district: Date Palm and Guava Demonstration Centre, announced in FY2025-26. Fatehabad district: Guava Demonstration Centre at Government Garden Nursery on Uklana road, Bhuna, established 27.10.2020. Sirsa district: Centre of Excellence for fruits (Citrus & Pomegranate), Mangiana, established 22.06.2013.
The dragonless Aemond claims Vhagar, which leads to a fight between Alicent and Rhaenyra's children where Luke slashes one of Aemond's eyes out. They are all brought before Viserys in a mass gathering, where a furious Alicent demands one of Luke's eyes to be taken out as retribution, arguing with Rhaenyra who defends her kids. After Viserys refuses to abide by Alicent's demand, she grabs his Valyrian steel dagger and rushes towards Luke, but is blocked by Rhaenyra. Aemond asserts that the loss of his eye in exchange for gaining a dragon was a fair trade, and Viserys considers the matter settled under those conditions. He also declares that anyone claiming Rhaenyra's children to be bastards will lose their tongue. Viserys reinstates Otto as his Hand (as Lyonel had recently perished in a fire), where he and Alicent conspire to solidify their family's positions at court while Rhaenyra and Daemon unite to counter their influence over the court. Six years later, Viserys' health has greatly declined, as his face is partially disfigured and he is frequently bedridden. Otto and Alicent have de facto control over royal matters, as Viserys frequently drinks milk of the poppy and has declining mental acuity. Corlys' younger brother Vaemond petitions the crown to be named as Corlys' heir instead of Luke, who he accuses of being a bastard. Otto presides over the matter and is inclined to rule against Luke, but a frail Viserys shows up to the throne room to oversee the matter himself, walking to the Iron Throne with great difficulty and support from Daemon.
==== De-epithelialization technique ==== Labial reduction by means of the de-epithelialization of the tissues involves cutting the epithelium of a central area on the medial and lateral aspects of each labium minus (small lip), either with a scalpel or with a medical laser. This labiaplasty technique reduces the vertical excess tissue, whilst preserving the natural rugosity (corrugated free-edge) of the labia minora, and thus preserves the sensory and erectile characteristics of the labia. Yet, the technical disadvantage of de-epithelialization is that the width of the individual labium might increase if a large area of labial tissue must be de-epithelialized to achieve the labial reduction.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.